The hospice M&A market has attracted strong buyer interest for years, and that interest has not slowed. Deal volume has risen consistently, EBITDA multiples have expanded, and hospice’s position within the broader continuum of care continues to make it a favored target for both private equity and strategic buyers.
But a strong market does not guarantee a clean close. The most preventable reason deals fall apart, even well-priced deals with motivated buyers, is documentatio
